ARTA
SCLN

A.R.T. Advisors’s Sciclone Pharmaceuticals Inc SCLN Stock Holding History

A.R.T. Advisors’s Portfolio SCLN Stock Details SCLN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q2 		– Sell
-24,944
Closed -$274K – 1814
2016
Q1 		$274K Buy
+24,944
New +$222K 0.01% 1071
2015
Q3 		– Sell
-74,008
Closed -$726K – 1778
2015
Q2 		$726K Buy
74,008
+44,764
+153% +$408K 0.02% 844
2015
Q1 		$259K Buy
+29,244
New +$233K 0.01% 1155
2014
Q3 		– Sell
-16,098
Closed -$84K – 1672
2014
Q2 		$84K Sell
16,098
-6,000
-27% -$29.2K ﹤0.01% 1226
2014
Q1 		$100K Buy
+22,098
New +$107K 0.01% 1238

Other funds holding SCLN

Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
LSV Asset Management
LSV Asset Management Chicago, Illinois $46.4B AUM 27.74% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

A.R.T. Advisors's SCLN Position: Q2 2016 in Review

A.R.T. Advisors sold out of Sciclone Pharmaceuticals Inc (SCLN) in Q2 2016, closing a stake of 24,944 shares — an estimated $274K sold.

A.R.T. Advisors first reported a position in SCLN in Q1 2014 and held it in 5 quarters. The position peaked at $726K in Q2 2015. 151 funds tracked by Wall St. Rank hold SCLN as of Q2 2016.

  • A.R.T. Advisors reported no remaining Sciclone Pharmaceuticals Inc position as of Q2 2016 after selling out during the quarter.
  • A.R.T. Advisors sold 24,944 Sciclone Pharmaceuticals Inc shares in Q2 2016, an estimated $274K.
  • A.R.T. Advisors first reported a position in Sciclone Pharmaceuticals Inc in Q1 2014 and held it in 5 quarters.
  • A.R.T. Advisors's Sciclone Pharmaceuticals Inc position peaked at $726K in Q2 2015.
  • 151 funds tracked by Wall St. Rank held Sciclone Pharmaceuticals Inc as of Q2 2016.

Based on A.R.T. Advisors's 13F filing for Q2 2016, filed 15 Aug 2016.